Elevated high-affinity LFA-1 and ICAM-1 levels in Roquin^san/+tumors. (A) Tumor samples have increased frequency of high-affinity LFA-1. Representative flow cytometric analyses and frequency of high-affinity LFA-1 expression on CD4⁺ cells from recombinant ICAM-1 binding assay (10 μg/mL of murine recombinant ICAM-1; n = 5 tumor-free; n = 4 nontumorous [non-tumor]; and n = 4 tumorous [tumor] samples). (B) Concomitant increased expression of ICAM-1 on B220⁺ cells in Roquin^san/+ tumors as shown in representative flow cytometric analyses and frequencies. (B-C) MFI of ICAM-1 on B-cell subsets (n = 5 tumor-free; n = 5 nontumorous; and n = 7 tumorous samples). (D) Incubating wild-type Peyer’s patch cells with Lovastatin during ICAM-1 binding assay verifies reduction in high-affinity LFA-1 levels on CD4⁺ T cells with minimal differences in cell viability (n = 5, wild type). (E) Left graph shows a time course of change in tumor size after treatment with lovastatin (2 mg/kg, intraperitoneal, every other day for 2 weeks) compared with the untreated control group. Lovastatin-treated mice were further subgrouped based on the following criteria: no response (<25% reduction in area or growth), partial response (25% to 60% reduction in area), or full response (>60% reduction in area) at the final time point (week 6). The right graph further compares each response type with the untreated control group. (F) Exemplary regressed tumor is shown in sonograms. Error bars in panels A-E represent the SEM. Data are pooled from at least 2 independent experiments. *P < .05; **P < .01; ***P < .001; ****P < .0001.